pembrolizumab,tislelizumab,lenvatinib,sorafenib
merck,beigene,eisai,bayer,novartis
['rationale-301', 'hcc', 'leap-002']
encouraging efficacy data with anti-pd1 antibody in combination or as monotherapy in hcc: rationale-301 and leap-002 presented at #esmo22. 
The European Society for Medical Oncology (ESMO) is the leading organisation for cancer education and information, supporting the oncology community’s work.